Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Håkon Astrup
  • Jon Berggren
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Weak report across the board

Patrik Ling

Getinge (Buy, TP: SEK150.00) - A little soft on the margin

Getinge’s Q2 report was mixed. Sales and order intake were better than expected but adj. EBITA margin fell short of expectations. The company announced additional cost-saving initiatives in the Surgical Workflows (SW) operation and said some effect from these actions should be visible in H2. We believe the company is executing on its turnaround, but that 2019 is still a transition year and there will be a bumpy road for some time. We reiterate our BUY recommendation and have raised our target price to SEK150 (145) on our outer-year forecasts.

Eivind Sars Veddeng ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Stefan Gauffin

Nothern Lights

Nurhayati Wan

Getinge

Jake Strole

Morningstar | Getinge's Second-Quarter Results Mixed, but Profitability Set to Improve Into 2020; Shares Expensive

No-moat Getinge reported results that largely met our expectations, with strong revenue growth overshadowed by margin performance that remained muted. As we update our model, we don't expect to make major changes but could see a slight uptick in our SEK 97 per share fair value estimate. We view shares as somewhat overvalued following the strong performance year to date. The company posted another quarter of above-trend revenue growth, with a top line that grew 4% organically led by the acute care therapies segment. From a regional perspective, growth in the Americas and in Asia-Pacific drove ...

Patrik Ling

Getinge (Buy, TP: SEK150.00) - A little soft on the margin

Getinge’s Q2 report was mixed. Sales and order intake were better than expected but adj. EBITA margin fell short of expectations. The company announced additional cost-saving initiatives in the Surgical Workflows (SW) operation and said some effect from these actions should be visible in H2. We believe the company is executing on its turnaround, but that 2019 is still a transition year and there will be a bumpy road for some time. We reiterate our BUY recommendation and have raised our target price to SEK150 (145) on our outer-year forecasts.

Jake Strole

Morningstar | Getinge's Second-Quarter Results Mixed, but Profitability Set to Improve Into 2020; Shares Expensive

No-moat Getinge reported results that largely met our expectations, with strong revenue growth overshadowed by margin performance that remained muted. As we update our model, we don't expect to make major changes but could see a slight uptick in our SEK 97 per share fair value estimate. We view shares as somewhat overvalued following the strong performance year to date. The company posted another quarter of above-trend revenue growth, with a top line that grew 4% organically led by the acute care therapies segment. From a regional perspective, growth in the Americas and in Asia-Pacific drove ...

Jake Strole

Getinge's Second-Quarter Results Mixed, but Profitability Set to Improve Into 2020; Shares Expensive

No-moat Getinge reported results that largely met our expectations, with strong revenue growth overshadowed by margin performance that remained muted. As we update our model, we don't expect to make major changes but could see a slight uptick in our SEK 97 per share fair value estimate. We view shares as somewhat overvalued following the strong performance year to date. The company posted another quarter of above-trend revenue growth, with a top line that grew 4% organically led by the acute car...

Patrik Ling

Getinge (Buy, TP: SEK145.00) - Strong growth in sales and orders

Getinge reported Q1 2019 earnings yesterday, with organic sales growth of c6% and organic order intake growth of c7.6%, better than both we and the market expected. Adjusted operating expenses rose more slowly than sales, also a positive. On the negative side, the company reported that the divestment of the mesh operation did not materialise. We keep our BUY recommendation and have raised our target price to SEK145 (SEK125) on our forecast adjustments.

Jake Strole

Getinge's First-Quarter Results Put the Firm on Track to Exceed Our Full-Year Estimates

Getinge's first-quarter results surpassed our full-year expectations on revenue and were consistent with our outlook that calls for modest margin expansion for the full year. We don't intend to make many changes to our model, but with 6% organic revenue growth, or roughly 14% as reported, management's 2%-4% organic growth target appears too conservative. Any adjustments we make will likely move our SEK 97 per share fair value estimate higher by a low- to mid-single-digit percentage for this no-m...

1 director bought

A director at Getinge Ab bought 26,509 shares at 81.830SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Håkon Astrup
  • Jon Berggren
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Weak report across the board

Eivind Sars Veddeng ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Stefan Gauffin

Nothern Lights

Håkon Astrup ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Stefan Gauffin

Northern Lights

Christer Magnergård ...
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Montgomery
  • Niclas Gehin
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Frank Maaø ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Nurhayati Wan

Getinge

With a more favourable environment, GETINGE AB improves to Positive

GETINGE AB (SE), a company active in the Medical Equipment industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date June 14, 2019, the closing price was SEK 145.00 and its potential was estimated at SEK 156.56.

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

null

Nurhayati Wan

Getinge

MarketLine Department

Hill-Rom Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Hill-Rom Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Hill-Rom Holdings, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive adv...

GlobalData Department

Getinge AB (GETI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Getinge AB (Getinge) is a medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia equipment, heart-lung machines with accompanying disposables, equipment and instruments for cardiac surgery, vascular surgery; cardiac assist devices; patient lifting devices, hospital beds, stretchers and couches, mattresses for treating and preventing pressure sores, disinfectors, sterilization equipmen...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/12/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting.Under ITEM 7, the board of directors seeks approval to distribute all shares in the wholly-owned subsidiary Arjo to the Company's shareholders. ECGS endorses the view of the board of directors that the proposal to split the Company into two separate listed companies (Getinge and Arjo) could enhance the prerequisites to succesfully develop the respective businesses. In addition, ECGS is generally supportive towards corporate spin-offs as they give s...

Expert Corporate Governance Service (ECGS)

Etude l' AG du 15/08/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting. Under ITEM 7, it is proposed to add a conversion clause, providing the opportunity to convert series A shares into series B shares, to the Company's Articles of Association. As a matter of principle, we welcome the addition of such a conversion clause. The clause is intended to facilitate the spin-off of the Company's Acute Care Therapies business ("Arjo") to its shareholders. Under the Swedish Companies Act conversion is only possible on a 1:1 basi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch